CoChat

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus

Open access
Onoviran, Olusola F., Li, Dongming, Toombs Smith, Sarah, Raji, Mukaila A. · 2019 · Therapeutic Advances in Chronic Disease
Cited by 57

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Elderly patients with diabetes are at high risk of polypharmacy because of multiple coexisting diseases and syndromes. Polypharmacy increases the risk of drug–drug and drug–disease interactions in these patients, who may already have age-related sensory and cognitive deficits; such deficits may delay timely communication of early symptoms of adverse drug events. Several glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been approved for diabetes: liraglutide, exenatide, lixisenatide, dulagluatide, semaglutide, and albiglutide. Some are also approved for treatment of obesity. The current review of literature along with clinical case discussion provides evidence supporting GLP-1 RAs as diabetes medications for polypharmacy reduction in older diabetes patients because of their multiple pleiotropic effects on comorbidities (e.g. hyperlipidemia, hypertension, and fatty liver) and syndromes (e.g. osteoporosis and sleep apnea) that commonly co-occur with diabetes. Using one medication (in this case, GLP-1 RAs) to address multiple conditions may help reduce costs, medication burden, adverse drug events, and medication nonadherence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2040622319862691

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 57

Metadata

Authors
Onoviran, O. F., Li, D., Toombs Smith, S., & Raji, M. A.
Venue
Therapeutic Advances in Chronic Disease
Published
2019-01
Volume
10
Pages
2040622319862691-2040622319862691
ISSN
  • 2040-6223 (ISSN-L)
  • 2040-6231
OpenAlex
W2960517189
Cited by
57
References
48
FWCI
5.33
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. https://app.cochat.ai/papers/10.1177/2040622319862691
The paper
Onoviran, O. F., Li, D., Toombs Smith, S., & Raji, M. A. (2019). Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. Therapeutic Advances in Chronic Disease. https://doi.org/10.1177/2040622319862691

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.